Further to Decision 43 COM 9A, this document presents a report on the implementation of the Upstream Process requests, including the Pilot Projects, since the 43rd session of the World Heritage ...
Scaling a viral vector process from benchtop to clinical supply isn't a bigger version of monoclonal antibody (mAb) manufacturing, but an entirely different analytical challenge. Cell and gene therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results